Parallax Volatility Advisers
KERX

Parallax Volatility Advisers’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Parallax Volatility Advisers’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-60,000
Closed -$303K – 4151
2015
Q4 		$303K Hold
60,000
– – ﹤0.01% 1735
2015
Q3 		$211K Hold
60,000
– – ﹤0.01% 1797
2015
Q2 		$599K Buy
+60,000
New +$643K ﹤0.01% 1544

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's KERX Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 53,243 shares — an estimated $200K sold.

Parallax Volatility Advisers first reported a position in KERX in Q2 2015 and held it in 4 quarters. The position peaked at $479K in Q2 2015. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 53,243 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $200K.
  • Parallax Volatility Advisers first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
  • Parallax Volatility Advisers's Keryx Biopharmaceuticals Inc position peaked at $479K in Q2 2015.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.